Serum biomarkers confirming stable remission in inflammatory bowel disease

Serum biomarkers confirming stable remission in inflammatory bowel disease

Abstract Crohn's disease (CD) and ulcerative colitis (UC) have a chronic-remittent course. Optimal management of inflammatory bowel diseases (IBD) relies on early intervention, treat-to-target strategies and a tight disease control. However, it is challenging to assess the risk of relapses in i...

Full description

Bibliographic Details
Main Authors:	Christoph Kessel, Miha Lavric, Toni Weinhage, Markus Brueckner, Sytze de Roock, Jan Däbritz, Jakob Weber, Sebastiaan J. Vastert, Dirk Foell
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-03-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-021-86251-w

Similar Items

Peripheral monocyte functions and activation in patients with quiescent Crohn's disease.
by: David Schwarzmaier, et al.
Published: (2013-01-01)

Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease
by: Jack S. Cornish, et al.
Published: (2020-01-01)

New Insights on CD8+ T Cells in Inflammatory Bowel Disease and Therapeutic Approaches
by: Rosaely Casalegno Garduño, et al.
Published: (2021-10-01)

An Examination of Diet for the Maintenance of Remission in Inflammatory Bowel Disease
by: Natasha Haskey, et al.
Published: (2017-03-01)

Potential of nutraceutical products for irritable bowel syndrome remission maintenance
by: A. I. Ulyanin, et al.
Published: (2018-08-01)

Effect of irritable bowel syndrome on sleep quality and quality of life of inflammatory bowel disease in clinical remission
by: Ali Zargar, et al.
Published: (2019-01-01)

Social and personal factors of stable remission for people with drug addictions.
by: Petrova, H. A., et al.
Published: (2015-07-01)

Iron Deficiency Is Common During Remission in Children With Inflammatory Bowel Disease
by: Emma Wikholm MD, et al.
Published: (2016-03-01)

Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
by: Mitchell R. K. L. Lie, et al.
Published: (2018-03-01)

Granulocyte Macrophage Colony-Stimulating FactorâActivated CD39+/CD73+ Murine Monocytes Modulate Intestinal Inflammation via Induction of Regulatory T CellsSummary
by: Toni Weinhage, et al.
Published: (2015-07-01)

The Receptor for Advanced Glycation Endproducts (RAGE) Contributes to Severe Inflammatory Liver Injury in Mice
by: Toni Weinhage, et al.
Published: (2020-06-01)

Dietary Strategies for Maintenance of Clinical Remission in Inflammatory Bowel Diseases: Are We There Yet?
by: Konstantinos Gkikas, et al.
Published: (2020-07-01)

Prolonged P-Wave and QT Dispersion in Children with Inflammatory Bowel Disease in Remission
by: Helen Aghdasi Bornaun, et al.
Published: (2017-01-01)

The efficacy (not confirmed) of dietary-nutritional treatment of Irritable Bowel Syndrome
by: Virginia López Bastida, et al.
Published: (2017-10-01)

Juvenile Arthritis Patients Suffering from Chronic Inflammation Have Increased Activity of Both IDO and GTP-CH1 Pathways But Decreased BH4 Efficacy: Implications for Well-Being, Including Fatigue, Cognitive Impairment, Anxiety, and Depression
by: Gerdien A. H. Korte-Bouws, et al.
Published: (2019-01-01)

Gene expression analysis of peripheral cells for subclassification of pediatric inflammatory bowel disease in remission.
by: Pieter P E van Lierop, et al.
Published: (2013-01-01)

Persistent Abnormalities of Fatty Acids Profile in Children With Idiopathic Nephrotic Syndrome in Stable Remission
by: Stefano Turolo, et al.
Published: (2021-01-01)

Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
by: Marie Truyens, et al.
Published: (2021-09-01)

Nuclear and Mitochondrial Circulating Cell-Free DNA Is Increased in Patients With Inflammatory Bowel Disease in Clinical Remission
by: Zuzana Vrablicova, et al.
Published: (2020-12-01)

Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease
by: Marianna Lucafò, et al.
Published: (2021-05-01)

Calprotectin Is a Useful Tool in Distinguishing Coexisting Irritable Bowel-Like Symptoms from That of Occult Inflammation among Inflammatory Bowel Disease Patients in Remission
by: Lars-Petter Jelsness-Jørgensen, et al.
Published: (2013-01-01)

Response, partial remission and remission in different antidepressants
by: Hui-YuChuang, et al.
Published: (2010)

Autoimmune disease-associated gene expression is reduced by BET-inhibition
by: Janneke G.C. Peeters, et al.
Published: (2016-03-01)

A myostatin-CCL20–CCR6 axis regulates Th17 cell recruitment to inflamed joints in experimental arthritis
by: Michelle Fennen, et al.
Published: (2021-07-01)

Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease
by: Renske W. M. Pauwels, et al.
Published: (2020-12-01)

Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study
by: Kwangwoo Nam, et al.
Published: (2021-01-01)

A systematic review and meta-analysis on 6-thioguanine nucleotides levels and clinical remission in inflammatory bowel disease
by: Maria Manuela Fernandes Estevinho
Published: (2021)

Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease
by: Cristina Segú-Vergés, et al.
Published: (2021-04-01)

Long-term implications of structured transition of adolescents with inflammatory bowel disease into adult health care: a retrospective study
by: Lukas Schütz, et al.
Published: (2019-07-01)

Sialoblastoma- long-term follow-up and remission for a rare salivary malignancy
by: Linda Granowetter, et al.
Published: (2011-04-01)

The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases
by: Shuro Yoshida, et al.
Published: (2018-04-01)

High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
by: Aze Wilson, et al.
Published: (2021-02-01)

Bone mass density variability in activity vs remission of the disease in young patients with inflammatory bowel disease: Case series
by: Iulia Soare, et al.
Published: (2020-10-01)

Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle
by: Gyeol Seong, et al.
Published: (2020-06-01)

Irritable bowel syndrome-like symptoms associated with endoscopic activity predict ulcerative colitis relapse in patients with clinical remission
by: Nobuhiko Fukuba, et al.
Published: (2017-10-01)

Confirmation of Initial Stable Adsorption Structures of Leucine and Tyrosine Adsorbed on a Cu(110) Surface
by: Hangil Lee, et al.
Published: (2020-02-01)

Stable isotope labeling confirms mixotrophic nature of streamer biofilm communities at alkaline hot springs
by: Florence eSchubotz, et al.
Published: (2015-02-01)

Stable isotope labeling confirms mixotrophic nature of streamer biofilm communities at alkaline hot springs
by: Schubotz, Florence, et al.
Published: (2015)

Confirmation theory & confirmation logic
by: Lin, Chao-tien
Published: (2010)

Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease
by: Omeed Alipour, et al.
Published: (2021-08-01)